Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients

Managed Care (Langhorne, Pa.)
|February 17, 2018
PubMed

Hemlibra demonstrates how far antibody science has progressed. Genentech's drug, approved late last year, connects two clotting factors to prevent the devastating bleeds in hemophilia patients with inhibitors. The high price may be offset by avoided costs in patients with factor VIII inhibitors.